SwanBio Therapeutics, a Philadelphia, PA-based gene therapy company, raised $56M in Series B funding.
The round, which brings total financing raised to date to $133 million, was led by Syncona Limited and Mass General Brigham Ventures.
The company intends to use the funds for ongoing evolution into a fully integrated research and development organization, with an initial focus on the clinical advancement of SBT101, including plans to dose patients in a Phase 1/2 trial by the end of this year, and for further progress of the pipeline applying learnings from SBT101 to other monogenic disorders, as well as polygenic disorders.
SwanBio Therapeutics is a gene therapy company that aims to bring life-changing treatments to people with inherited neurological conditions. The company is advancing a pipeline of gene therapies, designed to be delivered intrathecally, that can address targets within both the central and peripheral nervous systems. This approach has the potential to be applied broadly across three disease classifications – spastic paraplegias, monogenic neuropathies, and polygenic neuropathies. Its lead program is being advanced toward clinical development for the treatment of adrenomyeloneuropathy (AMN).
SBT101 is the first clinical-stage AAV-based gene therapy candidate for the treatment of adrenomyeloneuropathy (AMN). The investigational drug has been designed to compensate for the disease-causing ABCD1mutation in people living with AMN. This mutation disrupts the function of spinal cord cells and other tissues, leading to nerve degeneration, causing loss of mobility in adulthood, incontinence, debilitating pain, and sexual dysfunction. Patients often experience adrenal gland dysfunction as well. In early 2022, the FDA cleared SwanBio’s Investigational New Drug application for SBT101 and granted Orphan Drug and Fast Track designations to SBT101. eyond SBT101, SwanBio is developing a pipeline of gene therapy candidates designed to be delivered intrathecally to targets in both the central and peripheral nervous systems, with an initial focus on spinal cord-related disorders like AMN.
FinSMEs
19/05/2022